{"id":"W4411260753","doi":"10.1016/s1470-2045(25)00209-8","title":"Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trial","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Exelixis","keywords":"Atezolizumab; Cabozantinib; Medicine; Oncology; Prostate cancer; Prostate; Internal medicine; Cancer; Immunotherapy; Pembrolizumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001888883,0.001653639,0.00259814,0.0003101149,0.0003986126,0.001501848,0.0009261275,0.001563445,0.009521199],"category_scores_gemma":[0.00219122,0.0005433029,0.003276874,0.0004887244,0.0008505369,0.00133061,0.0003726295,0.003293792,0.00152861],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009372815,"about_ca_system_score_gemma":0.001125997,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001992417,"about_ca_topic_score_gemma":0.006639562,"domain_scores_codex":[0.9992015,0.0004441752,0.00004156196,0.0001274167,0.00006072687,0.0001245798],"domain_scores_gemma":[0.9988,0.0004217038,0.0002246126,0.0001175493,0.00008742748,0.0003487707],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9736322,0.001660279,0.0006558142,0.000911666,0.002865249,0.00004483098,0.00007240257,0.00040056,0.001803768,0.0001419176,0.002098516,0.0157127],"study_design_scores_gemma":[0.966359,0.02881799,0.0019326,0.00004260781,0.001162272,0.00005668181,0.00003933482,0.000230036,0.0001939328,0.0001886115,0.0009588628,0.0000181304],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9711033,0.01579599,0.0009261697,0.001520262,0.000817179,0.001745866,0.00359379,0.0002769218,0.004220487],"genre_scores_gemma":[0.9842378,0.004308586,0.001280118,0.001425996,0.0004346851,0.001272559,0.002726145,0.00005303228,0.004261081],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009521199,"threshold_uncertainty_score":0.03185153,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.3279042008534256,"score_gpt":0.5471206174015985,"score_spread":0.2192164165481729,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}